Patents Assigned to Hadasit Medical Research Services and Development Ltd.
  • Patent number: 8461166
    Abstract: Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are further disclosed. The disclosed EGFR-TK inhibitors comprise a polyalkylene glycol moiety and/or a hydroxy-containing moiety and are characterized by improved solubility, biostability and bioavailability. Processes of preparing the disclosed EGFR-TK inhibitors and of radiolabeling same, via, for example, one-step radiosyntheses, are also disclosed.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: June 11, 2013
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Eyal Mishani, Samar Dissoki, Galith Abourbeh, Alexander Levitzki
  • Publication number: 20130137593
    Abstract: The present invention provides compositions, methods and kits for diagnosing cancer, specifically the diagnosis of colorectal cancer (CRC). More specifically, the invention provides simple assays, with high sensitivity and specificity for CRC, wherein a panel of microRNA (miRNA) are used as biomarkers.
    Type: Application
    Filed: April 14, 2011
    Publication date: May 30, 2013
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Aviram Nissan, Stella Mitrani Rosenbaum, Nadia Ilyayev, David Halle
  • Patent number: 8435791
    Abstract: A highly controlled and precise system, device and method for tissue and cellular alteration and treatment below or at surfaces with a laser. The present invention is characterized by ultra low levels of collateral damage as defined by physiologically relevant tests that measure tissue viability. The operation of the present invention is based on spectrally confining the interaction between laser energy and a targeted tissue including an essential element for physiologically relevant tests for monitoring tissue viability.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: May 7, 2013
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Eithan Galun, Aaron Lewis, Evelyne Zeira, Alexandra Manevitch, Artium Khatchatouriants, Yitzchak Hemo
  • Patent number: 8420092
    Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: April 16, 2013
    Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd.
    Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
  • Publication number: 20130084583
    Abstract: An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed.
    Type: Application
    Filed: November 27, 2012
    Publication date: April 4, 2013
    Applicants: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yissum Research Development Company of the H, Hadasit Medical Research Services and Developm
  • Publication number: 20130078637
    Abstract: The present invention relates to genotypes associated with resistance to antipsychotic-induced parkinsonism and other extrapyramidal symptoms induced by antipsychotics, and use of said genotypes for assessment of patient populations. The methods and kits of the invention are based on identifying in a sample obtained from a subject, specific SNPs in the ZFPM2 and RGS2 genes.
    Type: Application
    Filed: May 26, 2011
    Publication date: March 28, 2013
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Bernard Lerer, Lior Greenbaum, Anna Alkelai
  • Patent number: 8377934
    Abstract: The invention relates to methods of treatment and prevention of aquatic mold infections in aquatic organisms and methods of disinfecting equipment used in raising aquatic organisms. The methods comprise use of one or more stilbene derivatives, including 4,4?-bis-(1,3,5-triazinylamino)stilbene-2,2?-disulfonic acid derivatives.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: February 19, 2013
    Assignees: State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization, Hadasit Medical Research Services and Development Ltd.
    Inventors: Itzhack Polacheck, Simon Tinman, Rama Falk
  • Patent number: 8372389
    Abstract: The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: February 12, 2013
    Assignees: Hadasit Medical Research Services and Development Ltd., Christian-Albrechts-Universitat Zu Kiel
    Inventors: Jonathan H. Axelrod, Eithan Galun, Stefan Rose-John, Ytzhack Marmary
  • Publication number: 20130023469
    Abstract: Activators of the AKT/mTOR pathway, in particular leptin, are useful in methods and compositions for increasing regeneration of liver, increasing liver mass or improving liver function, or a combination thereof.
    Type: Application
    Filed: September 21, 2010
    Publication date: January 24, 2013
    Applicants: Hadasit Medical Research Services & Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Eli Pikarsky, Yehudit Bergman, Neri Laufer, Yuval Gielchinsky, Efraim Weitman
  • Patent number: 8354111
    Abstract: The present invention relates to novel family of homologous cell attachment chimeric peptides. In particular, the present invention relates to chimeric peptides, each comprising synthetic peptides comprising (a) an M-tide comprising an amino acid sequence that is at least 80% homologous to the amino acid sequence selected from the group consisting of: SEQ ID NO:1, 2 and 37; and (b) a core haptide comprising an amino acid sequence homologous to amino acid sequences at the carboxy termini of the and E chains of fibrinogen or other proteins comprising C-termini that are homologous to said fibrinogen sequences, wherein the M-tide and the core haptide originate from the same protein. The synthetic peptides are linked to one another thereby providing the chimeric peptides of the invention which does not occur in the native protein as a continuous sequence. The present invention further discloses pharmaceutical compositions comprising said chimeric peptides and uses thereof.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: January 15, 2013
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Raphael Gorodetsky
  • Patent number: 8304384
    Abstract: The present invention relates to the regulatory role of caspase-8 in infection by intracellular pathogen, inflammation and wound healing.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: November 6, 2012
    Assignees: Yeda Research and Development Co., Ltd, Hadasit Medical Research Services and Development Ltd.
    Inventors: David Wallach, Rinat Abramovitch, Eitan Galun, Tehila Ben Moshe, Hila Barash
  • Patent number: 8299237
    Abstract: The invention relates to nucleic acid sequences comprising NF-?B binding sites derived from the MGMT promoter region and uses thereof as decoy molecules in the treatment of cancer and immune-related disorders. More particularly, the invention relates to nucleic acid sequences as well as to modified oligonucleotides (ODNs) comprising NF-?B binding sites derived from the MGMT promoter region, and uses thereof as decoy molecules for inhibiting NF-?B enhanced expression of MGMT. The invention further relates to compositions, kits and screening methods using the NF-?B binding sites of the invention or ODNs comprising the same for treating cancer and immune related disorders.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: October 30, 2012
    Assignee: Hadasit Medical Research Services & Development Ltd.
    Inventor: Iris Lavon
  • Publication number: 20120245380
    Abstract: The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject.
    Type: Application
    Filed: May 31, 2012
    Publication date: September 27, 2012
    Applicant: Hadasit Medical Research Services & Development Ltd.
    Inventors: Yaron ILAN, Ehud ZIGMOND, Richard B. SILVERMAN, Hejun LU
  • Patent number: 8257742
    Abstract: A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: September 4, 2012
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd.
    Inventors: Haim Danenberg, Morey Schachter, Gershon Golomb
  • Publication number: 20120207715
    Abstract: The present invention relates to systems, methods and storage media for preserving and prolonging viability of cultured matrix dependent cells including multipotent progenitor cells, such as mesenchymal stem cells. The system and method of the invention are effective in ambient room temperature and apply during storage and shipment of said cells. The storage medium of the invention comprises fibrin microbeads and culture medium, and is suitable for the maintenance and storage of matrix dependent cells. The methods of the invention comprise use of said system, for attaching matrix dependent cells to fibrin microbeads in culture so as to form cell-fibrin microbead complexes.
    Type: Application
    Filed: February 8, 2012
    Publication date: August 16, 2012
    Applicant: Hadasit Medical Research Services & Development Ltd.
    Inventor: Raphael GORODETSKY
  • Publication number: 20120203082
    Abstract: A transdermal antenna may be partially inserted into a cavity in the body of a mammal to receive wireless data transmissions from devices located within the body and relay the data to devices located outside of the body. The transdermal antenna may include a first antenna which may be inserted inside of the body cavity and receive radio frequency data transmissions from devices located inside the body. The transdermal antenna may conduct the received data transmissions to a relay mechanism located outside of the body using coaxial cables, waveguides or a combination of both. The relay mechanism may relay the conducted data transmissions to a receiver device located outside of the body by using a wire connection, such as a coaxial cable, or a wireless communication link via a transceiver coupled to a second antenna.
    Type: Application
    Filed: October 3, 2010
    Publication date: August 9, 2012
    Applicants: MICRON E.M.E. LTD., Hadasit Medical Research Services & Development Ltd.
    Inventors: Noam Livneh, Yoav Mintz, Vered Bar-Bracha, Arik Bracha
  • Patent number: 8211865
    Abstract: The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: July 3, 2012
    Assignee: Hadasit Medical Research Services & Development, Ltd.
    Inventors: Yaron Ilan, Ehud Zigmond, Richard B. Silverman, Hejun Lu
  • Patent number: 8202724
    Abstract: A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells. The method comprises ex-vivo providing the stem cells with conditions for cell proliferation and with at least one copper chelator in an amount and for a time period for permitting the stem cells to proliferate and, at the same time, for reducing a capacity of the stem cells to differentiate.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: June 19, 2012
    Assignees: Gamida Cell Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Tony Peled, Eitan Fibach, Avi Treves
  • Patent number: 8193147
    Abstract: The invention provides an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide and a Copolymer 1-related polypeptide, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising the active agent, for use in treating a muscular dystrophy disease or disorder.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: June 5, 2012
    Assignee: Hadasit Medical Research Services & Development Ltd.
    Inventor: Yoram Nevo
  • Publication number: 20120101589
    Abstract: The present invention relates to methods of coating prosthetic devices with dried fibrin. Particularly, the present invention relates to methods of coating the surface of prosthetic devices with fibrin and drying the fibrin-coated prosthetic devices at moderately-high temperatures for extended periods of time under low atmospheric pressure to obtain prosthetic devices coated with stable cross-linked fibrin capable of binding cells and thereby capable of integrating into tissues.
    Type: Application
    Filed: May 12, 2010
    Publication date: April 26, 2012
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Raphael Gorodetsky